Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference
December 08 2020 - 4:05PM
via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or
the “Company”) (NYSE American: TMBR), a biopharmaceutical company
focused on the development and commercialization of treatments for
rare and orphan dermatologic diseases, today announcedthat it will
be presenting at the 13th annual LD Micro Main Event investor
conference on Tuesday, December 15, 2020 at 10:40 AM EST / 7:40 AM
PST. John Koconis, Chief Executive Officer of Timber Pharma, will
be presenting to a live, virtual audience.
Register
here: ve.mysequire.com/
The Main Event will feature a new and unique
format, with companies presenting for 10 minutes, followed by 10
minutes of Q&A by a panel of investors and analysts.
"The time has finally come to do something
different in the virtual conference world. Let’s see if we can pull
off something that can be enjoyed by both executives and investors
alike,” stated Chris Lahiji, Founder of LD, now a wholly owned
subsidiary of SRAX, Inc.
The Main Event will take place on December 14th
and 15th, exclusively on the Sequire Virtual Events
platform.
View Timber Pharmaceuticals profile here:
http://www.ldmicro.com/profile/TMBR
Profiles
powered by LD Micro
About Timber Pharmaceuticals,
Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic
diseases. The Company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and localized scleroderma. For more
information, visit www.timberpharma.com.
About LD Micro/SEQUIRE
LD Micro began in 2006 with the sole purpose of
being an independent resource to the microcap world. What started
as a newsletter highlighting unique companies, has transformed into
the pre-eminent event platform in the space. For more information,
please visit ldmicro.com.
The upcoming Main Event will be highlighting a new
format that will benefit both executives and the investors tuning
in from all over the globe.
In September 2020, LD Micro. Inc. was acquired by
SRAX, Inc., a financial technology company that unlocks data
and insights for publicly traded companies. Through its premier
investor intelligence and communications
platform, Sequire, companies can track their
investors’ behaviors and trends and use those insights to engage
current and potential investors across marketing channels. For more
information on SRAX,
visit srax.com and mysequire.com.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's Form 10-Q filed on
August 18, 2020 and its other filings with the Securities and
Exchange Commission. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information,
contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
Source:Timber Pharmaceuticals via
LD Micro
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024